Cidara Therapeutics Inc (NASDAQ: CDTX) kicked off on Friday, down -5.53% from the previous trading day, before settling in for the closing price of $25.70. Over the past 52 weeks, CDTX has traded in a range of $10.14-$28.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 28.02% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 73.13%. With a float of $7.68 million, this company’s outstanding shares have now reached $12.21 million.
In an organization with 38 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 81.13%, operating margin of -35743.71%, and the pretax margin is -61454.97%.
Cidara Therapeutics Inc (CDTX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cidara Therapeutics Inc is 40.80%, while institutional ownership is 53.73%. The most recent insider transaction that took place on Mar 11 ’25, was worth 36,542. In this transaction COO & CLO of this company sold 1,664 shares at a rate of $21.96, taking the stock ownership to the 14,674 shares. Before that another transaction happened on Mar 11 ’25, when Company’s CHIEF SCIENTIFIC OFFICER sold 1,773 for $21.96, making the entire transaction worth $38,940. This insider now owns 16,215 shares in total.
Cidara Therapeutics Inc (CDTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 73.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 31.18% during the next five years compared to 1.30% growth over the previous five years of trading.
Cidara Therapeutics Inc (NASDAQ: CDTX) Trading Performance Indicators
Take a look at Cidara Therapeutics Inc’s (CDTX) current performance indicators. Last quarter, stock had a quick ratio of 3.87. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1049.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -29.07, a number that is poised to hit -1.68 in the next quarter and is forecasted to reach -8.98 in one year’s time.
Technical Analysis of Cidara Therapeutics Inc (CDTX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.25 million. That was better than the volume of 0.14 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 74.88%. Additionally, its Average True Range was 1.77.
During the past 100 days, Cidara Therapeutics Inc’s (CDTX) raw stochastic average was set at 68.64%, which indicates a significant increase from 63.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 104.63% in the past 14 days, which was higher than the 78.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.98, while its 200-day Moving Average is $18.03. However, in the short run, Cidara Therapeutics Inc’s stock first resistance to watch stands at $25.45. Second resistance stands at $26.61. The third major resistance level sits at $27.28. If the price goes on to break the first support level at $23.62, it is likely to go to the next support level at $22.95. The third support level lies at $21.79 if the price breaches the second support level.
Cidara Therapeutics Inc (NASDAQ: CDTX) Key Stats
The company with the Market Capitalisation of 314.91 million has total of 12,547K Shares Outstanding. Its annual sales at the moment are 1,280 K in contrast with the sum of -169,830 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -23,480 K.
